TAG:
laboratory industry
2011’s Top 10 Lab Stories Point to a Busy 2012
By Robert Michel | From the Volume XIX No. 1 – January 9, 2012 Issue
CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,” it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinica…
LabCorp’s BeaconLBS Aims To Manage Genetic Tests
By Joseph Burns | From the Volume XVIII No. 17 – December 19, 2011 Issue
CEO SUMMARY: BeaconLBS is a new business created by Laboratory Corporation of America. It says it wants to help health insurance plans manage molecular diagnostics and genetic testing. BeaconLBS is now recruiting other clinical labs to join its network and is meeting with payers to offer …
Anatomic Path Insourcing Expected to Be Ongoing
By Robert Michel | From the Volume XVIII No. 16 – November 28, 2011 Issue
CEO SUMMARY: Insourcing of anatomic pathology services by office-based physicians has been especially prevalent and is increasing among three specialties (gastroenterology, urology, and dermatology), according to a survey conducted last month. Survey respondents also indicated that the tr…
Palmetto GBA Announces Molecular Test Registry
By Joseph Burns | From the Volume XVIII No. 16 – November 28, 2011 Issue
CEO SUMMARY: Palmetto GBA, the nation’s largest Medicare Administrative Contractor (MAC), is asking labs in the J1 jurisdiction to submit applications for each molecular test they run. Molecular assays will receive a unique five-digit alpha-numeric identifier (Z-code) that will be enter…
Rosetta Genetics, Aureon Biosciences, Plus Diagnostics, Atherotech, Sequenom
By Robert Michel | From the Volume XVIII No. 14 – October 17, 2011 Issue
ROSETTA GENOMICS TO LAY OFF 35 EMPLOYEES TO CUT EXPENSES AND SHIFT MORE FUNDING toward sales of its proprietary molecular tests, Rosetta Genomics says it will eliminate 35 jobs. The company, based in Israel, operates a clinical laboratory in Philadelphia, Pe…
Are Prosecutors Afraid of Big and Little Lab Firms?
By Robert Michel | From the Volume XVIII No. 14 – October 17, 2011 Issue
CEO SUMMARY: Settlements in the big whistleblower suits involving major lab companies typically generate national headlines. But seldom do the views of the “quiet majority” of lab owners and lab executives get much attention. These are the majority of lab professionals workin…
Thermo Fisher, Intrinsic Bioprobes, Kaiser Permanente, UCSF, CLMA, ASCLS
By Robert Michel | From the Volume XVIII No. 13 – September 26, 2011 Issue
THERMO FISHER BUYS INTRINSIC BIOPROBES, CONTINUES BUYING SPREE IT’S ANOTHER ACQUISITION FOR Thermo Fisher Scientific, Inc., of Waltham, Massachusetts. It purchased Intrinsic Bioprobes, Inc., of Rochester, New York, earlier this month. A m…
Will Lawsuits Re-shape Current Lab Practices?
By Robert Michel | From the Volume XVIII No. 9 – July 5, 2011 Issue
CEO SUMMARY: Recent events in California, triggered by a lab whistleblower lawsuit filed in 2005 and unsealed in 2009, provide the latest example of how these lawsuits and related government enforcement actions can cause fundamental changes in the pricing and marketing p…
Quest Diagnostics Settles Medi-Cal Qui Tam Case
By Robert Michel | From the Volume XVIII No. 8 – June 13, 2011 Issue
CEO SUMMARY: On May 19, the California Attorney General announced a $241 million agreement with Quest Diagnostics Incorporated that represents the largest settlement in the history of California’s False Claims Act. At issue in this whistle- blower lawsuit were allegations that Qu…
What Future for Deeply-Discounted Lab Prices?
By R. Lewis Dark | From the Volume XVIII No. 8 – June 13, 2011 Issue
IN THE LABORATORY TESTING INDUSTRY, there is probably no single issue that causes more rancor than the regular use of deeply-discounted pricing of laboratory tests by a certain cohort of laboratory companies. This fault line in our industry is quite distinct. Those managers and pathologists in lab o…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized